Enclomiphene Dosage: What Clinical Trials Used

PrescribedRX is a telehealth platform; prescriptions are written by licensed clinicians and filled by licensed partner pharmacies.

Short answer: The enclomiphene dosage in published trials of enclomiphene citrate was 12.5 mg or 25 mg by mouth once a day, one early trial also tested 6.25 mg, and one registered phase 3 protocol started at 12.5 mg and moved to 25 mg at week 6 if morning testosterone was under 300 ng/dL (Wiehle 2013; ZA-301). The enclomiphene offered through PrescribedRX is compounded, and your provider sets the dose.

This page reports the doses that published trials and registered study protocols used. It is not a dosing instruction and not medical advice. For what those trials measured over time, see our page on enclomiphene results by timepoint.

Is there a standard enclomiphene dose?

The doses in published research come from trial protocols, listed below, and those protocols were written for the men enrolled in each study. The enclomiphene offered through PrescribedRX is a compounded tablet, and a licensed provider decides whether it is appropriate for you and sets the dose.

Our guide to what enclomiphene is covers its background.

What doses did the enclomiphene trials use?

All of these trials enrolled men with secondary hypogonadism, meaning low testosterone with low or normal LH.

Study	Design and men	Daily dose the trial used	Compared with	Length
Wiehle 2013	Phase II, randomized, single-blind; 48 men enrolled, 44 per protocol	6.25 mg, 12.5 mg or 25 mg	AndroGel testosterone gel, 5 g	6 weeks
Kaminetsky 2013	Phase IIB, randomized, open-label, fixed dose; 12 men who had used testosterone gel	25 mg	Testosterone gel	24 weeks (6 months)
Wiehle 2014 (ZA-203)	Phase II, randomized, double-blind, placebo-controlled; 83 enrolled	12.5 mg or 25 mg	1% testosterone gel and placebo	12 weeks (3 months)
Kim 2016 (ZA-304 and ZA-305)	Two parallel phase III, randomized, double-blind, placebo-controlled trials; overweight men aged 18 to 60	12.5 mg or 25 mg	AndroGel 1.62% and placebo	16 weeks
ZA-301 (registry)	Phase 3, randomized, double-blind, placebo-controlled; 151 enrolled	12.5 mg, moved to 25 mg at week 6 if morning testosterone was under 300 ng/dL	Placebo	12 to 18 weeks
ZA-300 (registry)	Phase III, open-label safety study; 499 enrolled	12.5 mg, titrated to 25 mg if needed	None (open label)	6 months

Sources: Wiehle 2013; Kaminetsky 2013 with dose and length from the Hohl 2025 study table; ZA-203 registry and Hohl 2025 for Wiehle 2014; Hohl 2025 and Kim 2016; ZA-301; ZA-300.

Wiehle 2013: three doses for six weeks

This phase II trial enrolled men whose testosterone was under 350 ng/dL. The authors reported that all three doses increased testosterone. On day 42, morning total testosterone averaged 604 ± 160 ng/dL in men taking 25 mg and 500 ± 278 ng/dL in men on gel, a difference that was not statistically significant (p = 0.23). They also reported that the effects on LH and testosterone lasted at least one week after stopping (Wiehle 2013).

Kaminetsky 2013: 25 mg for six months

This small phase IIB study enrolled 12 men who had been using testosterone gel. The abstract describes it as a fixed-dose study, and the study table in the 2025 meta-analysis lists the dose as enclomiphene citrate 25 mg a day against testosterone gel for 24 weeks, with 7 men on enclomiphene and 5 on gel (Hohl 2025). At 6 months, the authors reported mean total testosterone of 525 ± 256 on enclomiphene and 545 ± 268 on gel, and only the enclomiphene group showed increased LH and FSH (Kaminetsky 2013).

Wiehle 2014 (ZA-203): 12.5 mg or 25 mg for three months

The registry record for this trial describes a capsule of either 12.5 mg or 25 mg once daily for 3 months, compared with testosterone gel and placebo, in men with morning testosterone under 250 ng/dL (ZA-203). The published paper reported that enclomiphene raised morning testosterone and LH to levels similar to 1% testosterone gel, increased FSH and LH, and conserved sperm counts (Wiehle 2014).

Kim 2016: 12.5 mg or 25 mg for 16 weeks

Two parallel phase III trials compared two doses of enclomiphene citrate with AndroGel 1.62% in overweight men aged 18 to 60 with morning testosterone of 300 ng/dL or less. The meta-analysis study table lists the two doses as 12.5 mg and 25 mg a day (Hohl 2025). The authors reported that total testosterone increased in all treatment groups at 16 weeks, that LH and FSH rose on enclomiphene and fell on gel, and that sperm concentration stayed in the normal range on enclomiphene (Kim 2016).

Enclomiphene 12.5 mg vs 25 mg: how did trials choose between them?

Some trials randomized men to a fixed 12.5 mg or 25 mg dose. Others started everyone at 12.5 mg and raised the dose based on a testosterone reading. The registry records describe these rules:

Protocol	Dose the protocol started at	Rule for moving to 25 mg
ZA-301 (phase 3)	12.5 mg	At week 6, men who had not reached morning testosterone of 300 ng/dL or more were up-titrated to 25 mg
ZA-300 (phase III safety)	12.5 mg	“Titrated to 25 mg if needed”; the dose “may be increased from 12.5 mg to 25 mg if indicated”
ZA-203 (phase II)	12.5 mg or 25 mg, assigned	No titration; fixed dose for 3 months

Sources: ZA-301, ZA-300, ZA-203 on ClinicalTrials.gov.

These are research protocols written for trial participants, not instructions for anyone outside those studies. The registry records list the study drug as Androxal capsules, which is not the same product as a compounded tablet.

How long did men take enclomiphene in the trials?

Treatment periods in these studies ranged from 6 weeks (Wiehle 2013) to 6 months (Kaminetsky 2013; ZA-300). The 2025 meta-analysis of clomiphene and enclomiphene trials lists follow-up of 2 to 30 weeks (Hohl 2025). None of these sources reports results beyond that window.

What did trials check at each dose?

The trials measured blood hormones and, in several, semen. Kaminetsky 2013 measured testosterone, estradiol, FSH, LH and other hormones, plus sperm parameters at the same visits (Kaminetsky 2013).

The ZA-300 safety study lists its safety checks as physical and visual acuity exams, slit lamp eye exams, clinical laboratory tests and adverse event reporting (ZA-300). For what these numbers mean on a lab report, see normal testosterone levels.

What side effects were reported at these doses?

The 2025 meta-analysis summarizes adverse events by trial. For Kim 2016, it reports that 53 men (21%) had adverse events possibly, probably or definitely related to a study drug, and that none of these were severe or serious. For Wiehle 2014, it reports treatment-emergent adverse events in 9% to 20% of subjects across groups, including one mildly raised estradiol at 12.5 mg and one mild sinus headache at 25 mg (Hohl 2025).

Our enclomiphene side effects page covers what the trials reported in more detail.

How much enclomiphene should I take?

An article can’t answer that. The trial doses above were set by research protocols for specific groups of men. Your provider sets the dose. The enclomiphene plan page says the tablet is taken by mouth, once a day, at a dose your provider sets from your panel. If you are comparing it with testosterone itself, the TRT dosage guide covers testosterone, which is a different drug, and enclomiphene vs clomiphene explains how enclomiphene relates to clomiphene.

When should you talk to a doctor?

Tell your provider about any new or worsening symptom while taking it, and about every other medicine and supplement you use. Ask your provider before changing your dose. For a medical emergency, call 911. Our enclomiphene safety information page has more.

How does enclomiphene work with PrescribedRX?

It starts with a hormone panel. The $69 hormone panel covers total testosterone, LH, hematocrit and PSA, drawn at a Quest lab near you, and a licensed provider reads the results. Enclomiphene offered through PrescribedRX is a compounded tablet. Compounded medications are prepared by licensed pharmacies and are not FDA-approved. A licensed provider decides whether it is appropriate for you, and your provider sets the dose. Each renewal comes with a $69 follow-up panel, billed separately.

• Enclomiphene (compounded tablet, once daily): $387 every 3 months
• Health Assessment – TRT (Quest hormone panel): $69 per panel

Start with the $69 hormone panel, or read the enclomiphene plan details. You can also compare TRT costs or browse all testosterone treatments. Self-pay, and availability varies by state; the eligibility check confirms yours.

Sources

1. Wiehle R, Cunningham GR, Pitteloud N, et al. Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics. BJU Int. 2013;112(8):1188-1200. PubMed. Accessed Oct 2026.
2. Kaminetsky J, Werner M, Fontenot G, Wiehle RD. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med. 2013;10(6):1628-1635. PubMed. Accessed Oct 2026.
3. Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102(3):720-727. PubMed. Accessed Oct 2026.
4. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677-685. PubMed. Accessed Oct 2026.
5. Hohl A, Chavez MP, Pasqualotto E, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Arch Endocrinol Metab. 2025;69(5):e250093. PMC. Accessed Oct 2026.
6. ClinicalTrials.gov. NCT01270841 (ZA-203): Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism. clinicaltrials.gov. Accessed Oct 2026.
7. ClinicalTrials.gov. NCT01532414 (ZA-301): Phase III Study to Evaluate Morning Testosterone Normalization in Men With Secondary Hypogonadism. clinicaltrials.gov. Accessed Oct 2026.
8. ClinicalTrials.gov. NCT01534208 (ZA-300): Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism. clinicaltrials.gov. Accessed Oct 2026.

This article is for general information. It is not medical advice and it is not a recommendation for any particular treatment. Whether a treatment is appropriate for you is a decision for a licensed clinician who has reviewed your health history and current medications.